Grundmann R, Wienand P, Holland M, Meider G
Dtsch Med Wochenschr. 1986 Apr 25;111(17):659-64. doi: 10.1055/s-2008-1068507.
In a prospective study three different immunosuppressive schemata after renal transplantation were compared. In group A (47 patients) conventional treatment with azathioprin and steroids was administered; in group B (47 patients) antilymphocyte globulin (ALG) was additionally given for three weeks. In group C (47 patients) ALG-azathioprin-steroid administration lasted for a mean of nine days after the transplantation, followed by ciclosporin. One-year transplant survival rate was 59.6% in group A, 70.2% in group B and 89.4% in group C; one-year patients survival rate 95.7%, 89.4% and 100%, respectively. Thus conventional immunosuppression with ALG followed by ciclosporin was statistically significantly superior to the other two treatment schedules, both with respect to patient and transplant survival. This was also true of postoperative dialysis rate, which was lowest in group C, at 17%, compared with group A (85.1%) and group B (42.6%). Under the chosen study conditions there was no evidence of a negative effect of ciclosporin on long-term renal function.
在一项前瞻性研究中,对肾移植后三种不同的免疫抑制方案进行了比较。A组(47例患者)采用硫唑嘌呤和类固醇进行常规治疗;B组(47例患者)额外给予抗淋巴细胞球蛋白(ALG),持续三周。C组(47例患者)在移植后平均给予ALG-硫唑嘌呤-类固醇治疗9天,随后给予环孢素。A组的一年移植存活率为59.6%,B组为70.2%,C组为89.4%;一年患者存活率分别为95.7%、89.4%和100%。因此,就患者和移植存活率而言,先采用ALG然后用环孢素进行常规免疫抑制在统计学上显著优于其他两种治疗方案。术后透析率也是如此,C组最低,为17%,而A组为85.1%,B组为42.6%。在所选择的研究条件下,没有证据表明环孢素对长期肾功能有负面影响。